BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Jan 27, 2017
Clinical News

Defitelio: Ph III started

...Jazz began an open-label, international Phase III trial to compare 25 mg/kg/day IV Defitelio plus best...
...HSCT who are at high or very high risk of developing VOD. Patients will receive Defitelio...
...the conditioning regimen for ≥21 days and end therapy no later than 30 days post-HSCT. Defitelio...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Apr 4, 2016
Finance

1Q approvals

...to treat moderate to severe plaque psoriasis in adults Jazz Pharmaceuticals plc (NASDAQ:JAZZ) FDA approves Defitelio defibrotide...
BioCentury | Apr 4, 2016
Clinical News

Defitelio defibrotide regulatory update

...FDA approved an NDA from Jazz for Defitelio defibrotide to treat hepatic veno-occlusive disease (VOD) in patients...
...hematopoietic stem cell transplant (HSCT). On March 30, Jazz said it expected to start shipping Defitelio...
...hepatic VOD in adults and children undergoing HSCT. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Product: Defitelio defibrotide...
BioCentury | Mar 31, 2016
Company News

FDA approves Jazz's Defitelio

...FDA approved an NDA for Defitelio defibrotide from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to treat hepatic veno-occlusive disease...
...VOD) in patients with renal or pulmonary dysfunction after a hematopoietic stem cell transplant (HSCT). Defitelio...
...head of R&D and CMO Karen Smith told BioCentury that Jazz expects to begin shipping Defitelio...
BioCentury | Jan 11, 2016
Finance

Sowing season

...NASDAQ:ICPT) OCA obeticholic acid Primary biliary cirrhosis (PBC) PDUFA date 5/29/16 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Defitelio defibrotide...
BioCentury | Oct 19, 2015
Company News

Link Healthcare, Clinigen Group deal

...Link provides distribution and infrastructure for its own and partnered products, including liver disease drug defibrotide...
BioCentury | Oct 5, 2015
Clinical News

Defibrotide regulatory update

...FDA accepted and granted Priority Review to a rolling NDA for defibrotide from Jazz to treat...
...is March 31, 2016. The single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA is approved as Defitelio...
...in adults and children undergoing HSCT. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Product: Defibrotide ( Defitelio ...
BioCentury | Apr 6, 2015
Finance

Q is for quiet

...obeticholic acid Primary biliary cirrhosis (PBC) Submit NDA and MAA 2Q15 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Defitelio defibrotide...
Items per page:
1 - 10 of 122